As with any drug with psychoactive properties that is used to treat chronic disease, there is always the risk of developing addiction. The safety of cannabis use as a medical treatment is not well researched, and there is insufficient information on its long-term side effects [2] . Other drugs with psychoactive properties and addiction potential such as morphine are routinely used for a number of conditions such as cancer-related pain [12] . While there are concerns among healthcare professionals over the possibility of addiction, these are dealt with by limiting the drug's availability by making it subject to the Misuse of Drugs Act (MDA) [12] . This results in close supervision of patients who are prescribed such drugs [13] . In our opinion, cannabinoids with proven therapeutic efficacy should be made available but subject to other legislation such as such as the Controlled Substances Act (USA) [14] and the Misuse of Drugs Act in the UK [15] . These could then be tested scientifically under controlled conditions and their risk/ benefit balance defined rigorously. Funding from a neutral source such as the Health Research Board would help ensure the rigor of this research and the acceptability of the findings internationally. Only then can the true place of cannabinoids in medical therapeutics be determined.
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